Shindler Kenneth S

Kwok Alex, Chaqour Brahim, Khan Reas S, Aravand Puya, Dine Kimberly, Ross Ahmara G et al.

This study found resveratrol and SIRT1 overexpression protected retinal ganglion cells and vision in mice with indirect traumatic optic neuropathy. This suggests resveratrol could be a therapy for human traumatic optic neuropathy.

O'Neill Nuala, Meng Miranda, Chaqour Brahim, Dine Kimberly, Sarabu Neha, Pham Jennifer C et al.

Researchers found that smaller NEFH and SNCG promoters equally drive neuroprotective gene delivery to retinal ganglion cells in a glaucoma mouse model, improving RGC survival and vision. This allows for packaging larger therapeutic genes.

Meng Miranda, Chaqour Brahim, O'Neill Nuala, Dine Kimberly, Sarabu Neha, Ying Gui-Shuang et al.

This study compared Brn3a and RBPMS markers for counting retinal ganglion cells (RGCs). Both detect RGC loss in aging and optic neuropathy, but Brn3a offers more consistent manual counts, aiding glaucoma research.

Reggie Sara N, Avery Robert A, Bavinger James C, Jivraj Imran, Alfaro Cesar, Pistilli Maxwell et al.

OCT-detected retinal/choroidal folds were studied to differentiate mild papilledema from pseudopapilledema. Folds were common in papilledema but rare in pseudopapilledema, suggesting their presence indicates true papilledema.

Khan Reas S, Ross Ahmara G, Aravand Puya, Dine Kimberly, Selzer Evan B, Shindler Kenneth S

Repetitive mild head impacts or one severe impact in mice cause progressive retinal ganglion cell and vision loss, offering a reproducible model to test TON treatments.

Grinblat Gabriela A, Khan Reas S, Dine Kimberly, Wessel Howard, Brown Larry, Shindler Kenneth S

Intranasal ST266 protected retinal ganglion cells and vision after optic nerve injury in mice, suggesting a non-invasive neuroprotective treatment for various optic neuropathies.

McDougald Devin S, Dine Kimberly E, Zezulin Alexandra U, Bennett Jean, Shindler Kenneth S

SIRT1 gene therapy preserved visual function in optic neuritis, while NRF2 protected RGCs, offering distinct neuroprotective strategies for optic neuropathies despite not reducing inflammation or demyelination.

Zuo Ling, Khan Reas S, Lee Vivian, Dine Kimberly, Wu Wen, Shindler Kenneth S

SIRT1 activation delayed retinal ganglion cell loss and functional decline after optic nerve crush, reducing oxidative stress. This suggests SIRT1-activating drugs could treat traumatic optic nerve damage.

Dutt Mahasweta, Tabuena Philomela, Ventura Elvira, Rostami Abdolmohamad, Shindler Kenneth S

Studying experimental optic neuritis, early corticosteroid treatment before inflammation onset prevented retinal ganglion cell loss, but later treatment was less effective. This suggests chronic immunomodulation may be crucial.

Shindler Kenneth S, Ventura Elvira, Rex Tonia S, Elliott Peter, Rostami Abdolmohamad

SIRT1 activators protected retinal ganglion cells from damage in experimental optic neuritis, suggesting a novel neuroprotective strategy to prevent vision loss in patients, potentially alongside anti-inflammatory treatments.